In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 163-168

  Park, Yoon Sun ^a   Shin, Woon Seob ^a   Kim, Soo Ki ^b  

^a Kwandong University College of Medicine   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Antistaphylococcal activities; Methicillin resistance; Vancomycin

Indexed keywords

ECHINOMYCIN; METICILLIN; OXACILLIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; STAPHYLOCOCCUS AUREUS; TIME;

ANIMALS; ANTI-BACTERIAL AGENTS; ECHINOMYCIN; FEMALE; HUMANS; METHICILLIN RESISTANCE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 37549042011     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm421     Document Type: Article

References (26)

1. Witte W, Cuny C, Strommenger B et al. Emergence of a new community acquired MRSA strain in Germany. Euro Surveill 2004; 9: 16-8.
2. Crum NF. The emergence of severe, community-acquired methicillin-resistant Staphylococcus aureus infections. Scand J Infect Dis 2005; 37: 651-6.
3. El Solh AA, Choi G, Schultz MJ et al. Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: Role of bacterial pathogens. Crit Care Med 2007; 35: 490-6.
4. Warren DK, Guth RM, Coopersmith CM et al. Impact of a methicillin-resistant Staphylococcus aureus active surveillance program on contact precaution utilization in a surgical intensive care unit. Crit Care Med 2007; 35: 430-4.
5. Maclayton DO, Hall RG, II. Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus. Ann Pharmacother 2007; 41: 235-44.
6. Anstead GM, Owens AD. Recent advances in the treatment of infections due to resistant Staphylococcus aureus. Curr Opin Infect Dis 2004; 17: 549-55.
7. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
8. Aires de Sousa M, de Lencastre H. Bridges from hospitals to the laboratory: Genetic portraits of methicillin-resistant Staphylococcus aureus clones. FEMS Immunol Med Microbiol 2004; 40: 101-11.
9. Ivanitskaia LP, Krugliak EB, Ts M et al. Production of echinomycin-like substances by various types of actinomycetes. Antibiotiki 1961; 6: 393-7.
10. Dell A, Williams DH, Morris HR et al. Structure revision of the antibiotic echinomycin. J Am Chem Soc 1975; 97: 2497-502.
11. Kong D, Park EJ, Stephen AG et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res 2005; 65: 9047-55.
12. Jayasuriya H, Zink DL, Polishook JD et al. Identification of diverse microbial metabolites as potent inhibitors of HIV-1 Tat transactivation. Chem Biodiv 2005; 2: 112-22.
13. Kim JB, Lee GS, Kim YB et al. In vitro antibacterial activity of echinomycin and a novel analogue, YK2000, against vancomycin-resistant enterococci. Int J Antimicrob Agents 2004; 24: 613-5.
14. Lee YK, Hyung Park J, Tae Moon H et al. The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer. Biomaterials 2007; 28 1523-30.
15. Castillo U, Harper JK, Strobel GA et al. Kakadumycins, novel antibiotics from Streptomyces sp. NRRL 30566, an endophyte of Grevillea pteridifolia. FEMS Microbiol Lett 2003; 224: 183-90.
16. Minor PD, Dimmock NJ. Selective inhibition of influenza virus protein synthesis by inhibitors of DNA function. Virology 1977; 78: 393-406.
17. Fox KR, Gauvreau D, Goodwin DC et al. Binding of quinoline analogues of echinomycin to deoxyribonucleic acid. Role of the chromophores. Biochem J 1980; 191: 729-42.
18. Brown DF, Edwards DI, Hawkey PM et al. Guidelines for the laboratory diagnosis and susceptibility testing of methicillin-resistant Staphylococcus aureus (MRSA). J Antimicrob Chemother 2005; 56: 1000-18.
19. Hanaki H, Akagi H, Masaru Y et al. TOC-39, a novel parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1120-6.
20. Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006; 58: 338-43.
21. Volund A. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models. Biometrics 1978; 34: 357-65.
22. Rothstein DM, Farquhar RS, Sirokman K et al. Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection. Antimicrob Agents Chemother 2006; 50: 3658-64.
23. Park YS, Kim YH, Kim SK et al. A new antitumor agent: Methyl sulfonium perchlorate of echinomycin. Bioorg Med Chem Lett 1998; 8: 731-4.
24. Kim YB, Kim YH, Park JY et al. Synthesis and biological activity of new quinoxaline antibiotics of echinomycin analogues. Bioorg Med Chem Lett 2004; 14: 541-4.
25. Foster BJ, Clagett-Carr K, Shoemaker DD et al. Echinomycin: The first bifunctional intercalating agent in clinical trials. Invest New Drugs 1985; 3: 403-10.
26. Chang AY, Kim K, Boucher H et al. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: An Eastern Cooperative Oncology Group Study (E1587). Cancer 1998; 82: 292-300.